Associate Professor, Medicine, UCSD School of Medicine
Internal Medicine
Dr. Sunder R. Mudaliar, MD
|
|
Give Review
Sunder Mudaliar is an expert in the field of Internal Medicine. He researched medicine at Stanley Medical College SMC. He has 1 awards "Fellow (FACE)". Sunder R. Mudaliar, MD is also published. He has 99 publications published. The lastest publication: "Effects of tumor necrosis factor-alpha on glucose metabolism in cultured human muscle cells from nondiabetic and type 2 diabetic subjects.'
Publications
- A Novel Insulin Resistance Index to Monitor Changes in Insulin Sensitivity and Glucose Tolerance: the ACT NOW Study.
- Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects.
- Baseline Adiponectin Levels Do Not Influence the Response to Pioglitazone in ACT NOW.
- Changes in Insulin Sensitivity and Insulin Secretion with the Sodium Glucose Cotransporter 2 Inhibitor Dapagliflozin.
- Prediction of Diabetes Based on Baseline Metabolic Characteristics in Individuals at High Risk.
- Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 Diabetes and nonalcoholic fatty liver disease.
- Choice of early treatment regimen and impact on β-cell preservation in type 2 Diabetes.
- Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: Effects of pioglitazone and metformin treatment.
- Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers.
- Prevention of Diabetes with Pioglitazone in Act Now: Physiologic Correlates.
- Effect of Pioglitazone on Body Composition and Bone Density in Subjects with PreDiabetes in the ACT NOW Trial.
- Evolution of exenatide as a Diabetes therapeutic.
- Pioglitazone slows progression of atherosclerosis in preDiabetes independent of changes in cardiovascular risk factors.
- Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a rando...
- Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
- Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 Diabetes.
- The incretin hormones: from scientific discovery to practical therapeutics.
- Efficacy and Safety of Taspoglutide in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Plus Pioglitazone over 24 Weeks: T-Emerge 3 Trial.
- Significant insulin dose errors may occur if blood glucose results are obtained from miscoded meters.
- Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 Diabetes.
- Free fatty acid Metabolism in human skeletal muscle is regulated by PPARgamma and RXR agonists.
- Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 Diabetes intensively treated w...
- Modulation of circulating and adipose tissue adiponectin levels by antiDiabetic therapy.
- Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects.
- Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of Type 2 diabetic subjects.
- Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 Diabetes: a randomized, parallel-group, 24-week study.
- Impaired fatty acid Metabolism in type 2 diabetic skeletal muscle cells is reversed by PPARgamma agonists.
- Adipocyte differentiation-related protein in human skeletal muscle: relationship to insulin sensitivity.
- Dose-response relationships of inhaled insulin delivered via the Aerodose insulin inhaler and subcutaneously injected insulin in patients with type 2 Diabetes.
- Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of Type 2 diabet...
- Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue.
- Selective regulation of cellular and secreted multimeric adiponectin by antiDiabetic therapies in humans.
- Regulation of glycogen synthase activity in cultured skeletal muscle cells from subjects with type II Diabetes: role of chronic hyperinsulinemia and hyperglycemia.
- PPAR-gamma gene expression is elevated in skeletal muscle of obese and Type II diabetic subjects.
- Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 Diabetes.
- Intravenous glargine and regular insulin have similar effects on endogenous glucose output and peripheral activation/deactivation kinetic profiles.
- Acquired defects of glycogen synthase activity in cultured human skeletal muscle cells: influence of high glucose and insulin levels.
- Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs Diabetes trial participants with lower calcified coronary atherosclerosis.
- Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with Diabetes.
- Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabe...
- Troglitazone effects on gene expression in human skeletal muscle of type II Diabetes involve up-regulation of peroxisome proliferator-activated receptor-gamma.
- Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action.
- Glucose transport in cultured human skeletal muscle cells. Regulation by insulin and glucose in nondiabetic and non-insulin-dependent Diabetes mellitus subjects.
- Troglitazone regulation of glucose Metabolism in human skeletal muscle cultures from obese type II diabetic subjects.
- Regulation of skeletal muscle morphology in Type 2 diabetic subjects by troglitazone and metformin: relationship to glucose disposal.
- Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I.
- Peroxisome proliferator-activated receptor (PPAR) gamma and retinoid X receptor (RXR) agonists have complementary effects on glucose and lipid Metabolism in human skel...
- Retinoid X receptor expression in skeletal muscle of nondiabetic, obese and Type 2 diabetic individuals.
- Insulin and insulin-like growth factor-1 action on human skeletal muscle: preferential effects of insulin-like growth factor-1 in Type 2 diabetic subjects.
- Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 Diabetes (SYNCH...
- Effects of the rapid-acting insulin analog glulisine on cultured human skeletal muscle cells: comparisons with insulin and insulin-like growth factor I.
- Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with Type 2...
- Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 Diabetes.
- Effects of intensive insulin therapy alone and with added pioglitazone on renal salt/water balance and fluid compartment shifts in type 2 Diabetes.
- Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of Type 2 diabetic subjects.
- Impaired muscle glycogen synthase in type 2 Diabetes is associated with diminished phosphatidylinositol 3-kinase activation.
- New oral therapies for type 2 Diabetes mellitus: The glitazones or insulin sensitizers.
- Glucosamine regulation of glucose Metabolism in cultured human skeletal muscle cells: divergent effects on glucose transport/phosphorylation and glycogen synthase in n...
- Effects of tumor necrosis factor-alpha on glucose Metabolism in cultured human muscle cells from nondiabetic and type 2 diabetic subjects.
- Induction of insulin resistance in human skeletal muscle cells by downregulation of glycogen synthase protein expression.
- Glycogen synthase activity is reduced in cultured skeletal muscle cells of non-insulin-dependent Diabetes mellitus subjects. Biochemical and molecular mechanisms.
- Insulin therapy in type 2 Diabetes.
- Prognostic role of B-type natriuretic peptide levels in patients with type 2 Diabetes mellitus.
- Thiazolidinediones, peripheral edema, and type 2 Diabetes: incidence, pathophysiology, and clinical implications.
- Inhaled insulin in patients with asthma and chronic obstructive pulmonary disease.
- Effects of Colesevelam on Glucose Absorption and Hepatic/ Peripheral Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus.
- Diabetes treatments have differential effects on nontraditional cardiovascular risk factors.
- Young and elderly type 2 diabetic patients inhaling insulin with the AERx insulin Diabetes management system: a pharmacokinetic and pharmacodynamic comparison.
- Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial.
- Pharmacodynamic and pharmacokinetic properties of a premixed 85/15 human insulin preparation.
- Inhibition of glycogen synthase kinase 3 improves insulin action and glucose Metabolism in human skeletal muscle.
- GSK-3beta and control of glucose Metabolism and insulin action in human skeletal muscle.
- Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study.
- Lack of effect of leptin on glucose transport, lipoprotein lipase, and insulin action in adipose and muscle cells.
- Inhibition of LDL oxidation in vitro but not ex vivo by troglitazone.
- Acute and chronic effects of insulin on leptin production in humans: Studies in vivo and in vitro.
- Incretin therapies: effects beyond glycemic control.
- Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function.
- Association of posttraumatic stress disorder with increased prevalence of metabolic syndrome.
- Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsul...
- Combination therapy for type 2 Diabetes.
- Human VEGF gene expression in skeletal muscle: effect of acute normoxic and hypoxic exercise.
- Effect of acute exercise on citrate synthase activity in untrained and trained human skeletal muscle.
- Exercise adaptation attenuates VEGF gene expression in human skeletal muscle.
- Telmisartan effects on insulin resistance in obese or overweight adults without Diabetes or hypertension.
- New frontiers in the management of type 2 Diabetes.
- Assessment of capacity to consent to research among older persons with schizophrenia, Alzheimer disease, or Diabetes mellitus: comparison of a 3-item questionnaire wit...
- Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder.
- Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.
- A lifestyle intervention for older schizophrenia patients with Diabetes mellitus: a randomized controlled trial.
- Pioglitazone for Diabetes prevention in impaired glucose tolerance.
- Role of glycemic control and protein restriction in clinical management of Diabetic kidney disease.
- Inhaled insulin using AERx insulin Diabetes Management System (AERx iDMS).
- Pioglitazone: side effect and safety profile.
- Skeletal muscle GLUT1 transporter protein expression and basal leg glucose uptake are reduced in type 2 Diabetes.
- Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance.
- Increased Framingham 10-year risk of coronary heart disease in middle-aged and older patients with psychotic symptoms.
- Serum glucose control in Diabetic patients with cardiovascular disease: should we be less aggressive?
Schools
Madras Medical College
Stanley Med College Hospital
St Mary39s Hospital
University Of California San Diego
Conditions Treated
- Calcium Metabolism Disorders
- Diabetes Type 2
- Diabetic Retinopathy
- Hypercalcemia
- View All
Doctors Specialties
- Internal Medicine
Accepted Insurances
Awards
- Fellow (FACE)
Education
-
University of California San Diego -
Stanley Medical College SMC
Helpful Reviews
Similar Doctors
|
|
Dr. David A. Reynaldo, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Deanna K. Price, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shih T. Tang, MD |